Interstitial Lung Disease Program, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA.
J Bras Pneumol. 2011 Jan-Feb;37(1):100-9. doi: 10.1590/s1806-37132011000100015.
In patients with myositis, the lung is commonly involved, and the presence of anti-aminoacyl-tRNA synthetase (anti-ARS) antibodies marks the presence or predicts the development of interstitial lung disease (ILD). A distinct clinical entity-antisynthetase syndrome-is characterized by the presence of anti-ARS antibodies, myositis, ILD, fever, arthritis, Raynaud's phenomenon, and mechanic's hands. The most common anti-ARS antibody is anti-Jo-1. More recently described anti-ARS antibodies might confer a phenotype that is distinct from that of anti-Jo-1-positive patients and is characterized by a lower incidence of myositis and a higher incidence of ILD. Among patients with antisynthetase syndrome-related ILD, the response to immunosuppressive medications is generally, but not universally, favorable.
在肌炎患者中,肺部通常会受到累及,而抗氨酰基-tRNA 合成酶(anti-ARS)抗体的存在标志着间质性肺疾病(ILD)的存在或预测其发生。一种独特的临床实体——抗合成酶综合征,其特征为存在抗-ARS 抗体、肌炎、ILD、发热、关节炎、雷诺现象和技工手。最常见的抗-ARS 抗体是抗-Jo-1。最近描述的抗-ARS 抗体可能具有与抗-Jo-1 阳性患者不同的表型,其特征为肌炎发生率较低和ILD 发生率较高。在与抗合成酶综合征相关的ILD 患者中,免疫抑制药物的反应通常是有利的,但并非普遍如此。